NCT01243775 (BELOXAN) is a Phase 2 clinical trial of Belotaxel in Non-Small Cell Lung Cancer, sponsored by Chonnam National University Hospital.

Who is sponsoring NCT01243775?

NCT01243775 is sponsored by Chonnam National University Hospital.

What drugs are being tested in NCT01243775?

Interventions in NCT01243775: Belotaxel, Belloxa.

What condition does NCT01243775 study?

NCT01243775 studies Non-Small Cell Lung Cancer.

Is NCT01243775 still recruiting?

NCT01243775 is currently completed. Last updated 20 July 2015.

Are results published for NCT01243775?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2015-07-20 · How we verify

NCT01243775: BELOXAN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Trial of First Line Docetaxel and Oxaliplatin in Stage IV or Relapsed Non-Small Cell Lung Cancer

Completed Phase 2 Results posted Last updated 20 July 2015

What this trial tests

Phase 2 trial testing Belotaxel in Non-Small Cell Lung Cancer in 33 participants. Completed in 1 January 2013.

Timeline

1 November 2010

Primary endpoint
1 January 2013

1 January 2013

Quick facts

Lead sponsor	Chonnam National University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 November 2010
Primary completion	1 January 2013
Estimated completion	1 January 2013
Sites	1 location across South Korea

Drugs / interventions tested

Belotaxel — full drug profile →
Belloxa — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Chonnam National University Hospital

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Response Rate
Time frame: 6th week
RECIST version 1.1

Sponsor's own description

Lung cancer is the leading cause of cancer death in Korea as well as in other countries. About 80% of lung cancer is non-small cell lung cancer(NSCLC). The majority of patients with NSCLC require cytotoxic chemotherapy in the course of their illness. Combination chemotherapy using third generation anticancer drugs (paclitaxel, docetaxel, gemcitabine) with platinums(cisplatin or carboplatin) reached a plateau in their efficacy. Oxaliplatin, another platinum being used for colorectal, gastric and pancreatic cancer has lower adverse effects such as nausea and nephrotoxicity. In this phase II trial, we will observe efficacy and safety of docetaxel and oxaliplatin for patients with NSCLC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Chonnam National University Hospital trials

Trials by the same sponsor.

NCT07390461 — Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Pro · NA · not yet recruiting
NCT07482228 — Long-term Clinical Outcomes After Retinal Artery Occlusion · recruiting
NCT06954714 — Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions · NA · recruiting
NCT07002164 — Timing of Coronary Angiography in NSTEMI Complicated by Acute HF · NA · recruiting
NCT06227754 — OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01243775 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chonnam National University Hospital
Last refreshed: 20 July 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01243775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing